Effetti pleiotropici della metformina: hanno rilevanza clinica?

Abstract

Sixty years after its introduction in the therapeutic arsenal of type 2 diabetes, metformin remains the first-line treatment of type 2 diabetes according to national and international guidelines. Numerous obser¬vational studies have suggested that metformin may exert beneficial therapeutic effects on diabetes - and nondiabetes - related comorbidi¬ties, including cardiovascular, hepatic, neoplastic, and infectious dis¬eases. However, direct evidence of the pleiotropic effects of metformin from specific randomized controlled trials is still lacking.